Target attainment with continuously administered cefotaxime in critically ill patients – a retrospective cohort study
An erratum to this article was published (J Crit Care, Feb 2026 ↗)
Authors' conclusion
Our real-world analysis demonstrates that continuous administration of a standard dose of 6 g cefotaxime per day invariably ensures bactericidal plasma concentrations regarding Enterobacterales even with augmented renal function.
Study context
- Population
- Critically ill patients receiving continuously administered cefotaxime338 cefotaxime measurements
- Participants
- 105 patients
- Outcome
- Cefotaxime plasma levels >8 mg/l (>4xMIC breakpoint for Enterobacterales)
Main finding
As reported in the abstract
Plasma levels >8 mg/l
- Initial level >8 mg/l reached (96/96)
- all
- Follow-up measurements remaining >8 mg/l (236/237)
- nearly all
Observational data: associations, not effects.
Further findings
First plasma level >16 mg/l (8×MIC breakpoint for Enterobacterales) · first plasma level measurement
- First plasma level measurements surpassing 16 mg/l
- 90 % (85/96)
Association of estimated glomerular filtration rate (eGFR) with cefotaxime plasma levels
- Correlation between eGFR and cefotaxime plasma levels (highly significant, negative)
- −0.69 [−0.79 - −0.56]
- Plasma level variance attributed to eGFR (multiple linear regression)
- nearly 50 %
Original publication
Target attainment with continuously administered cefotaxime in critically ill patients – a retrospective cohort study. J Crit Care. Published 17 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →